Medindia

X

The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018

Tuesday, December 15, 2009 Drug News J E 4
Advertisement


WALTHAM, Mass., Dec. 14 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launches of several new agents, the atrial fibrillation drug market will increase more than sevenfold from $790 million in 2008 to $6.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Atrial Fibrillation finds that a strong pipeline of oral fixed-dose anticoagulants, most notably Boehringer Ingelheim's Pradaxa and Bayer/Johnson & Johnson's Xarelto, will drive significant market expansion. The market will also be driven by sales of the antiarrhythmic agent dronedarone (Sanofi-Aventis's Multaq), which will take share from class IC and class III antiarrhythmics to capture 11 percent of the total atrial fibrillation patient share in 2018. The report forecasts that Multaq will garner sales of $660 million in 2018.

"Multaq is the first antiarrhythmic to demonstrate a reduction in the risk of hospitalization due to cardiovascular causes in patients with paroxysmal or persistent atrial fibrillation," said Decision Resources Analyst Ben Kong, MBBS. "Physician enthusiasm for Multaq reflects the growing importance of clinically relevant outcomes in clinical trials involving antiarrhythmic therapies."

The report also finds that Cardiome/Astellas's Kynapid will provide an attractive alternative to electrical cardioversion, particularly in the U.S. intravenous cardioversion market, which is currently dominated by branded agents. In the U.S. alone, Kynapid will achieve sales of $130 million in 2018.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com .

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.com

SOURCE Decision Resources
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Circadin(R) - Prolonged Release Melatonin for Prim...
S
Give the Gift of Life This Holiday With Fashionabl...